Post by Randox

𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗪𝗲𝗲𝗸 𝟮𝟬𝟮𝟲 🗣️ Across the globe, approximately 590 million people are living with diabetes, with many more yet to be diagnosed. Using patented Biochip Technology, Randox have developed an array of Type 1 Diabetes Genetic Risk Score and autoantibody panels for the discrimination between Type 1 Diabetes and other non-autoimmune diabetes. 🔹 𝗧𝘆𝗽𝗲 𝟭 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗥𝗶𝘀𝗸 𝗦𝗰𝗼𝗿𝗲 (𝗚𝗥𝗦𝟭) Genotyping 10 SNPs from DNA and dried blood spots in under 3 hours. 🔹 𝗧𝘆𝗽𝗲 𝟭 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗔𝘂𝘁𝗼𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗣𝗮𝗻𝗲𝗹 Testing 4 highly sensitive autoantibody markers from a single sample. 🔹 𝗧𝘆𝗽𝗲 𝟭 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗥𝗶𝘀𝗸 𝗠𝘂𝗹𝘁𝗶-𝗘𝘁𝗵𝗻𝗶𝗰 (𝗚𝗥𝗦𝟮) A multi-ethnic panel in development with 47 SNPs spanning both HLA and non-HLA regions. With multi-analyte third-party controls also available, Randox delivers a comprehensive diabetes diagnostics portfolio that is transforming diabetes care through early, integrated insight. #DiabetesWeek #Diabetes #DiabetesDiagnostics